title: Drug eluting stents: To evolve or dissolve?
abstract: Currently, percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is the most commonly employed modality in the treatment of patients with coronary artery disease. PCI has come of age over the last four decades with enormous forays in the technology and drugs which have greatly enhanced its capability. Angioplasty and bare metal stents were plagued by high failure rates on account of restenosis leading to repeat revascularization procedures. Insights into pathophysiology of instent restenosis (ISR) and neointimal hyperplasia triggered the development of DES. The dreamlike remarkable reduction in ISR with DES was enthusiastically welcomed. Soon thereafter emerged the spectre of very late stent thrombosis (VLST) with DES. VLST was a new entity seen predominantly with DES and pathological insights as to the cause was instrumental in the development and efficacy of new generation DES. This review will highlight the evolution and present day DES for coronary interventions.
authors.affiliation: Consultant (Medicine & Cardio), Military Hospital (Cardio Thoracic Center), Pune 411040, India.
authors.forename: Prashant
authors.initials: P
authors.lastname: Bharadwaj
authors.affiliation: Senior Adviser (Medicine & Cardio), Military Hospital (Cardio Thoracic Center), Pune 411040, India.
authors.forename: D S
authors.initials: DS
authors.lastname: Chadha
keywords: Drug eluting stents; Evolution; Present day scenario